Form 4: Inotiv Inc. CFO Beth Taylor Reports Stock Option Grant

Beth Taylor, CFO of Inotiv Inc., reports the acquisition of stock options in the company.

Summary

• On February 21, 2025, Beth Taylor, the Chief Financial Officer of Inotiv, Inc., was granted stock options to purchase 6,500 shares of common stock.
• The exercise price of these options is $4.205 per share.
• The options vest over three years: 40% on February 21, 2026, 30% on February 21, 2027, and 30% on February 21, 2028, contingent upon continued employment.
• The expiration date for these options is February 21, 2035.
• Following this transaction, Ms. Taylor directly owns 6,500 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates confidence in the company's future, but doesn't provide any specific positive or negative information.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the industry to incentivize executives and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech and pharmaceutical services industry.
• Companies like Charles River Laboratories and Envigo (now part of Inotiv) also utilize stock options as part of their compensation strategy.
• The vesting schedule and exercise price are within the typical range for such grants.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the CFO to improve company performance.

Key Dates